AMDL Announces Teleconference to Discuss Its Second Quarter 2008 Financial Results
August 15 2008 - 5:04PM
PR Newswire (US)
TUSTIN, Calif., Aug. 15 /PRNewswire-FirstCall/ --
(http://www.amdl.com/) AMDL Inc. (AMEX:ADL), a world leader in
specialty pharmaceuticals with operations in Shenzhen, Jiangxi and
Jilin China, announced today its chief executive officer Gary
Dreher and chief financial officer Akio Ariura will host a
teleconference to discuss the Company's second quarter 2008
financial results. The call is scheduled for Tuesday, August 19,
2008 at 1:45 p.m. Pacific Standard Time (4:45 p.m. Eastern Time).
Existing or potential investors who would like to submit questions
prior to the call can do so by emailing Kristine Szarkowitz at . To
access the live call, please dial (877) 360-1705 in the U.S. or
(706) 902-3245 outside the U.S. and reference Conference ID#
60855707 five minutes before the call begins. The conference call
script will also be available on the Investor section of the AMDL
web site located at http://www.amdl.com/. Click on "Investor
Relations," then "Recent News" to access the Company's earnings
release which was issued today, August 15, 2008, and all other
accompanying financial and operating information. About AMDL: AMDL
Inc. is a global specialty pharmaceutical company. The company is
headquartered in Tustin, California with operations in Shenzhen,
Jiangxi, and Jilin, China. Along with its subsidiary Jade
Pharmaceutical Inc. (JPI), AMDL is devoted to the research,
development, manufacture, and marketing of diagnostic,
pharmaceutical, nutritional supplement, and cosmetic products
currently in China. The company employs approximately 320 people in
the U.S. and China. More information about AMDL and its products
can be obtained at http://www.amdl.com/. About Jade Pharmaceutical:
JPI has access to the fastest growing pharmaceutical and consumer
market in the world -- China. AMDL, through its Jade subsidiaries,
currently holds licenses for 133 products that are manufactured as
large volume injection fluids, tablets and other related products.
It currently manufactures over 20 key generic, over-the-counter and
supplemental pharmaceutical products under certified Chinese Good
Manufacturing Practice (CGMP) standards. AMDL Contact: Kristine
Szarkowitz Director-Investor Relations (M) (206) 310-5323
DATASOURCE: AMDL CONTACT: Kristine Szarkowitz, Director-Investor
Relations of AMDL, +1-206-310-5323, Web site: http://www.amdl.com/
Copyright
Amdl (AMEX:ADL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amdl (AMEX:ADL)
Historical Stock Chart
From Jul 2023 to Jul 2024